Utility of Genomic Profiling Use for Targeted Therapy in a Phase I Setting Reveals that ESCAT I/II Actionable Targets are Associated with Improved Outcomes
Findings from the CoPPO study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1653 results
InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure
A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma
FDA Approves Durvalumab for Muscle Invasive Bladder Cancer
Evidence for efficacy is based on the results from the NIAGARA study
A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI
Findings from the BARCODE1 study
EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin
Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007
Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer
Findings from the API-CAT study
Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas
Findings from the EREMISS study
FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC
Evidence for efficacy is based on the results from the PSMAfore study
EMA Recommends Extension of Indications for Pirtobrutinib
New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia
Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients with Oesophageal Squamous Cell Cancer
Findings from a biomarker analysis from the RATIONALE-302 study
Potential for Larger Gene Panels to Increase the Number of Molecularly Matched Therapies in Patients with Advanced Solid Tumours
Findings from the ProfiLER-02 study
FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET
Evidence for efficacy is based on the results from the CABINET study